NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N.
García-Closas M, et al. Among authors: real fx.
Lancet. 2005 Aug 20-26;366(9486):649-59. doi: 10.1016/S0140-6736(05)67137-1.
Lancet. 2005.
PMID: 16112301
Free PMC article.